The success of PDTx depends on provider acceptance, which in turn depends on the payer willingness to fairly compensate physicians for digital medicines. According to a Pear Therapeutics and Avalere survey, only 40% of payers were anticipated to cover PDTx in 2021, and 50% of them intended to do so within the next 18 months. The primary factor would be how well PDTx works clinically to improve patient outcomes. Given the recent flurry of regulatory and FDA approvals for PDTx and the willingness of the majority of payers to fund PDTx reimbursements in the future, it is comforting for PDTx producers as they continue to innovate.
Access Full Report at @ https://www.databridgemarketresearch.com/jp/reports/global-prescription-digital-therapeutics-dtx-market
Data Bridge Market Research analyses that the Prescription Digital Therapeutics (PDTx) Market is USD 3.90 billion in 2022, is expected to reach USD 17.16 billion by 2030, at a CAGR of 20.35% during the forecast period 2023 to 2030. The increasing acceptance and adoption of digital solutions in healthcare, along with the recognition of their efficacy, are driving the growth of the PDTx market. Healthcare providers and patients are becoming more open to incorporating digital therapeutics as a part of treatment plans.
Key Findings of the Study
Cost-effectiveness and accessibility are expected to drive the market's growth rate
Prescription digital therapeutics (PDTx) solutions provide a cost-effective alternative to traditional therapies, leading to reduced healthcare expenses. Leveraging digital platforms, PDTx eliminates the need for physical resources, such as medication or in-person consultations, lowering associated costs. Moreover, PDTx enhances accessibility by offering remote and self-managed treatment options, eliminating geographical barriers, and allowing patients to access therapy conveniently. This cost-effectiveness and improved accessibility make PDTx an appealing choice for healthcare providers, payers, and patients seeking efficient and affordable treatment options.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), GAIA AG (Germany), Welldoc’s Bluestar (U.S.),Solera Network (U.S.), Akili Interactive Labs, Inc. (U.S.), Better Therapeutics, LLC (U.S.), BigHealth (U.S.), Biofourmis (U.S.),Click Therapeutics, Inc. (U.S.), Happify, Inc. (U.S.), Limbix Health, Inc. (U.S.), Naturalcycles Nordic AB (Sweden), NuvoAir AB (Sweden), Sensyne Health plc. (U.K.), Xealth (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application, and patients.
- On the basis of mechanism the global prescription digital therapeutics (PDTx) market is segmented into input mechanisms and output mechanisms. The input mechanism segment is expected to dominate the market with a CAGR of 22.2% in the forecast period of 2023 to 2030 due to mechanisms' dependency on the patients’ data which are submitted in the software or app. After this, the app or software calculates or suggests the treatment option to the patients as well as monitors the disease symptoms of the patients.
- On the basis of category segment, the global prescription digital therapeutics (PDTx) market is segmented into medication augmentation, medication replacement. The hospital Pharmacy segment is expected to dominate the market with a CAGR of 7.3% in the forecast period of 2023 to 2030 due to pharmacological therapies as well as other therapies that support the treatment and patient health
In 2023, the medication augmentation segment is dominating the category segment of the global prescription digital therapeutics (PDTx) market
In 2023, the medication augmentation segment is expected to dominate the market owing to its use in combination with other pharmacological therapies as well as other therapies to support the treatment and patient health. Medication augmentation cannot replace drug therapies. with a CAGR of 22.2% in the forecast period of 2023- 2030
- On the basis of treatment segment, the global prescription digital therapeutics (PDTx) market is segmented into outpatient treatment and monotherapy. The outpatient treatment segment is expected to dominate the market with a CAGR of 22.2% in the forecast period of 2023-2030 owing to the prescription digital therapeutics are applications or software-based therapy that provide the treatment guide, therapies option according to patient's symptoms. Prescription digital therapeutics are designed in such a manner that they can be used anytime and anywhere without visiting doctor clinics.
- On the basis of software segment, the global prescription digital therapeutics (PDTx) market is segmented into software for respiratory conditions, software for mental health, software for opioid use disorder, software for diabetes, and others. Software for the diabetes segment is expected to dominate the market with a CAGR of 24.7% in the forecast period of 2023- 2020 due to global health expenditure on diabetes also increasing and research continuously working to find new and easy ways to treat the patients.
- On the basis of services segment the global prescription digital therapeutics (PDTx) market is segmented into behavioral microservices, and medical microservices. The behavioral microservices segment is expected to dominate the market with a CAGR of 22.1% in the forecast period of 2023-2030 due to this software-based application majorly work on the behavior studies and are the primary aspect of the therapy to find to the behavior of the patients in between the treatment.
- On the basis of app accessibility segment, the global prescription digital therapeutics (PDTx) market is segmented into android, iOS, windows. Android, iOS, windows is further sub–segmented into smartphone and tablet. In 2023, Hospital Pharmacy segment is expected to dominate the market with a CAGR of 7.3% in the forecast period of 2023 to 2030 due to cardiovascular diseases and disorders especially diabetes are the leading cause of death.
In 2023 android segment is expected to dominate the app accessibility segment in the global prescription digital therapeutics (PDTx) market
In 2023, android segment is expected to dominate the market owing to cardiovascular diseases and disorders especially diabetes are the leading cause of death. Research organizations and market players are continuously working to treat the metabolic conditions which have a direct impact on daily lives with a CAGR of 22.9% in the forecast period of 2023-2030.
- On the basis of app type segment the global prescription digital therapeutics (PDTx) market is segmented into native apps, and web apps. The native app segment is expected to dominate the market with a CAGR of 22.5% in the forecast period of 2023-2030 due to the personalized app which runs on the web server and can be stored locally on the operating system
- On the basis of application segment the global prescription digital therapeutics (PDTx) market is segmented into substance use disorder (SUD), opioid use disorder (OUD), attention-deficit/hyperactivity disorder (ADHD), alzheimer’s disease, major depressive disorder (MDD), insomnia, epilepsy, movement disorder, multiple sclerosis, migraine, autism spectrum disorder, oncology, inflammation, respiratory, cardiovascular, pain management, metabolic conditions, others. Metabolic conditions segment is expected to dominate the market a CAGR of 45.9% in the forecast period of 2023 to 2030 due to cardiovascular diseases and disorders especially diabetes are leading cause of the death. Research organizations and market players are continuously working to treat the metabolic conditions which have direct impact on the daily lives.
- On the basis of patient segment the global prescription digital therapeutics (PDTx) market is segmented into children and adults. Adults segment is expected to dominate the market with a CAGR of 22.6% in the forecast period of 2023 to 2030 due to studies on prescription digital therapeutics only adults data were taken and majority of adult population are using these types of therapeutics
Major Players
Data Bridge Market Research recognizes the following companies as the major prescription digital therapeutics (PDTx) market players in prescription digital therapeutics (PDTx) market are ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), GAIA AG (Germany), Welldoc’s Bluestar (U.S.)
Market Development
- Expansion- In 2020, Pear Therapeutics, Inc. received marketing authorization for RESET from the Health Science Authority (HSA) of Singapore. Through this marketing authorization the product will be available to wide population size.
- Advancements- In 2020, Akili Interactive Labs, Inc. received CE mark approval for EndeavorRx, a prescribed gaming therapy indicated for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients.
- Advancements- In 2020, According to Pear Therapeutics, Inc., Reset prescription digital therapies have received market approval from Singapore's Health Science Authority for the treatment of people with substance use disorders.
- Product Launch- In 2020, the Akili Interactive Labs, Inc. has launched the EndeavorRx for treatment of ADHD. The product designed by the company uses gaming therapy in order to improve the patient’s health. This therapy improves the patients’ attention by targeting and activating neural systems that improves the cognitive functioning.
- Collaboration- In 2020, Click Therapeutics, Inc. signed a collaborative agreement with Boehringer Ingelheim for the development and commercialization of CT-155 a novel prescription digital therapeutics indicated for treatment of Schizophrenia.
- Collaboration- In 2020, Voluntis went under collaboration with Bristol-Myers Squibb Company with an aim to create and investigate the prescription digital therapeutics for cancer treatment.
Regional Analysis
Geographically, the countries covered in the prescription digital therapeutics (PDTx) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in prescription digital therapeutics (PDTx) market during the forecast period 2023 - 2030
North America holds a dominant position in the prescription digital therapeutics (PDTx) market due to substantial research and development activities focused on PDTx and the region's high healthcare spending. The market is further propelled by the expansion of major companies and the emergence of new startups, fostering innovation and driving growth. These factors contribute to North America's accelerated growth rate in the prescription digital therapeutics market.
Asia-Pacific is estimated to be the fastest growing region in prescription digital therapeutics (PDTx) market the forecast period 2023 - 2030
The Asia-Pacific region is projected to witness significant growth from 2023 to 2030, driven by increasing healthcare costs and a rising burden of chronic diseases. The region's healthcare expenditure is escalating, creating a demand for cost-effective solutions like digital therapies. Furthermore, improvements in payment systems for digital therapies, such as reimbursement policies and insurance coverage, are expected to accelerate market expansion in the Asia-Pacific region, making these innovative treatments more accessible to patients.
For more detailed information about the prescription digital therapeutics (PDTx) market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-prescription-digital-therapeutics-dtx-market
